Álvaro Guillermo Zarama Valenzuela

Álvaro Guillermo Zarama Valenzuela

Auto-generated profile, based on publicly available information

Álvaro Guillermo Zarama Valenzuela

Department of Internal Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2025 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
ÁVÁlvaro Guillermo Zarama Valenzuela
Álvaro Guillermo Zarama Valenzuela
JGJavier Ricardo Garzón-Herazo
Javier Ricardo Garzón-Herazo
LCLina María Arbeláez Collazos
Lina María Arbeláez Collazos
PVPaula María Sánchez Villamil
Paula María Sánchez Villamil
OVOscar Mauricio Muñoz Velandia
Oscar Mauricio Muñoz Velandia
Background: Antibiotic stewardship programs recommend an early antibiotic de-escalation strategy in patients with hematologic malignancy-associated febrile neutropenia without documented infectious foci. Studies on its safety are scarce so there is low adherence to the recommendation. Methods: This is analytical observational retrospective cohort study. Adult patients who were started on meropenem were included. The primary outcome was a composite of in-hospital mortality, fever recurrence and intensive care unit admission. Univariate and multivariate analysis were performed to determine associations with the primary outcome, controlling for confounding variables. Results: One hundred twenty-eight patients (median age 51 years, interquartile range 34–63.5) were included, with lower occurrence of the primary outcome (21.2% vs 41.1%; P = 0.041) and intensive care unit admission (3% vs 16.8%; P = 0.044) in the early de-escalation group. In the multivariate analysis, de-escalation lowered the primary outcome risk (odds ratio [OR], 0.28; 95% confidence interval [95% CI], 0.09–0.85; P = 0.025), while neutropenia >10 days increased the risk (OR, 1.20; 95% CI, 1.09–1.33; P < 0.001). A lower risk was found in the autologous transplant (OR, 0.12; 95% CI, 0.21–0.63; P = 0.013) and the consolidation groups (OR, 0.09; 95% CI, 0.01–0.81; P = 0.031) compared to the induction chemotherapy group. Conclusions: In hematologic malignancy-associated febrile neutropenia patients who remain hemodynamically stable and without documented infectious foci, the early de-escalation from carbapenem may be associated with better clinical outcomes. Prospective and multicenter studies are needed to confirm these findings.

17 February 2026 in Revista Colombiana de Hematología y Oncología
Verified
Journal Article
Open access
PDF file
ÁZÁlvaro Zarama-Valenzuela
Álvaro Zarama-Valenzuela
DBDiego-Felipe Ballen
Diego-Felipe Ballen
LRLaura Rey-Vargas
Laura Rey-Vargas
WMWendy Montero-Ovalle
Wendy Montero-Ovalle
CCCarlos Alexander Huertas Caro
Carlos Alexander Huertas Caro
SSSilvia Serrano-Gómez
Silvia Serrano-Gómez
Introducción: el Atlas del Genoma del Cáncer (TCGA) ha sido un proyecto colaborativo internacional y multiinstitucional diseñado para caracterizar de manera integral las alteraciones moleculares de tumores de alta relevancia clínica. Este trabajo resume sus principales aportes, así como las limitaciones y retos derivados de su implementación. Métodos: se realizó una búsqueda estructurada en PubMed, EMBASE y Web of Science sobre TCGA, incluyendo publicaciones relacionadas con sus resultados, metodología, limitaciones y repercusiones clínicas y traslacionales. Resultados: se identificaron 88 publicaciones relevantes. TCGA analizó más de 20.000 muestras correspondientes a 33 tipos tumorales, integrando datos genómicos, transcriptómicos, epigenómicos y proteómicos. Entre sus contribuciones más relevantes destacan: a) la redefinición de la clasificación tumoral mediante subtipos moleculares, b) la identificación de mutaciones y vías de señalización con impacto terapéutico, como IDH1 en gliomas y subtipos moleculares en cáncer de mama, endometrio y estómago, c) la validación de biomarcadores pronósticos y predictivos, y d) el desarrollo de bases de datos abiertas que impulsaron estudios traslacionales y ensayos clínicos tipo canasta. En 2018, el Pan-cáncer Atlas evidenció similitudes moleculares transtumorales y consolidó el concepto de “genoma teranóstico”. Persisten limitaciones relacionadas con la representatividad poblacional, la heterogeneidad clínica y la aplicabilidad en entornos con recursos limitados. Conclusión: TCGA representó un hito en la oncología de precisión al transformar la comprensión de la biología tumoral y sentar las bases para el desarrollo de terapias dirigidas. Sus datos continúan siendo un recurso central para la investigación oncológica global.

16 April 2026 in Rare Tumors
Verified
Journal Article
Open access
ÁZÁlvaro Zarama-Valenzuela
Álvaro Zarama-Valenzuela
MAMonica Arévalo-Zambrano
Monica Arévalo-Zambrano
ÁCÁlvaro Cadena-Andrade
Álvaro Cadena-Andrade
AZAlejandro Zárate-Mesa
Alejandro Zárate-Mesa
Background: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the Philadelphia chromosome, typically progressing through chronic, accelerated, and blast phases. Blast crisis may be myeloid or lymphoid. Isolated central nervous system (CNS) involvement is rare and represents a diagnostic and therapeutic challenge. Case presentation: We report a 40-year-old man with no prior hematologic history who presented with four months of progressive lower-limb paresthesias, neuropathic pain, and subacute weakness impairing ambulation. Neurologic examination revealed asymmetric paraparesis, hyporeflexia, and distal hypoesthesia in a stocking distribution, consistent with a subacute asymmetric sensorimotor polyradiculoneuropathy. Complete blood count demonstrated marked leukocytosis with neutrophilia, left shift, and circulating blasts. Contrast-enhanced spinal magnetic resonance imaging showed extensive leptomeningeal enhancement. Cerebrospinal fluid (CSF) analysis revealed pleocytosis, hypoglycorrhachia, and elevated protein levels; flow cytometry identified 14% B-lymphoid blasts (CD34+, CD19+, CD20+, CD22+). Bone marrow aspirate and biopsy showed hypercellularity with trilineage hematopoiesis, basophilia, and small hypolobated megakaryocytes, without a significant increase in blasts (<5%). Cytogenetic analysis identified t (9; 22), and molecular testing confirmed the BCR::ABL1 p210 transcript, consistent with chronic-phase CML. An isolated CNS lymphoid blast crisis was diagnosed. Treatment with HyperCVAD (Block B only) plus dasatinib 140 mg daily resulted in neurologic improvement and hematologic normalization. After five cycles, CSF clearance was achieved, followed by consolidation with haploidentical allogeneic hematopoietic stem cell transplantation. The patient remains in complete remission. Conclusions: Isolated CNS blast crisis may represent the initial manifestation of CML. Prompt recognition through integrated neurologic, hematologic, and molecular evaluation is critical to enable timely, targeted therapy.

30 January 2023 in Universitas Médica
Verified
Journal Article
Open access
PDF file
AVAlvaro Guillermo Zarama Valenzuela
Alvaro Guillermo Zarama Valenzuela
DCDiana Paola Valencia Camacho
Diana Paola Valencia Camacho
Background: Rhupus is a rare rheumatologic disease defined as the overlap between rheumatoid arthritis and systemic lupus erythematosus. In this group of patients severe neurologic manifestations are unusual and difficult to diagnose in the clinical practice, with few cases reported in the literature. Case presentation: A 64-year-old Latin man presented with weight loss, dysphagia and impaired gait. After excluding solid neoplasia, electromyography and nerve conduction studies revealed mononeuritis multiplex in advanced stage. He fulfilled criteria for rhupus as the etiology and had a satisfactory response to treatment with steroids and a rehabilitation programme at 6 month follow up. Conclusion: Peripheral nervous system compromise must be recognized as a manifestation of autoimmune disease in order to make a timely diagnosis and treatment. Introducción: El rhupus es una enfermedad reumatológica rara que se define como la superposición de artritis reumatoide y lupus eritematoso sistémico. En esta población de pacientes, las manifestaciones neurológicas severas son inusuales y de difícil abordaje diagnóstico, con pocos casos reportados hasta el momento en la literatura. Presentación del caso: Hombre latino de 64 años de edad, quien se presentó al servicio de urgencias con pérdida de peso, trastorno de la deglución y la marcha. Inicialmente, se descartó una afectación neoplásica y se documentó la presencia de mononeuritis múltiple en fase avanzada, mediante la realización de electromiografía y neuroconducciones. Dentro de los estudios etiológicos cumplió criterios para rhupus y tuvo una respuesta satisfactoria al tratamiento con esteroides y terapias de rehabilitación a los seis meses de seguimiento. Conclusión: La afectación del sistema nervioso periférico debe reconocerse como una manifestación de las enfermedades autoinmunes para facilitar un diagnóstico rápido e intervenciones oportunas.

5 November 2025 in Infectious Diseases in Clinical Practice
Verified
Journal Article
Closed access
ÁVÁlvaro Guillermo Zarama Valenzuela
Álvaro Guillermo Zarama Valenzuela
JGJavier Ricardo Garzón-Herazo
Javier Ricardo Garzón-Herazo
LCLina María Arbeláez Collazos
Lina María Arbeláez Collazos
PVPaula María Sánchez Villamil
Paula María Sánchez Villamil
OVOscar Mauricio Muñoz Velandia
Oscar Mauricio Muñoz Velandia
Background: Antibiotic stewardship programs recommend an early antibiotic de-escalation strategy in patients with hematologic malignancy-associated febrile neutropenia without documented infectious foci. Studies on its safety are scarce so there is low adherence to the recommendation. Methods: This is analytical observational retrospective cohort study. Adult patients who were started on meropenem were included. The primary outcome was a composite of in-hospital mortality, fever recurrence and intensive care unit admission. Univariate and multivariate analysis were performed to determine associations with the primary outcome, controlling for confounding variables. Results: One hundred twenty-eight patients (median age 51 years, interquartile range 34–63.5) were included, with lower occurrence of the primary outcome (21.2% vs 41.1%; P = 0.041) and intensive care unit admission (3% vs 16.8%; P = 0.044) in the early de-escalation group. In the multivariate analysis, de-escalation lowered the primary outcome risk (odds ratio [OR], 0.28; 95% confidence interval [95% CI], 0.09–0.85; P = 0.025), while neutropenia >10 days increased the risk (OR, 1.20; 95% CI, 1.09–1.33; P < 0.001). A lower risk was found in the autologous transplant (OR, 0.12; 95% CI, 0.21–0.63; P = 0.013) and the consolidation groups (OR, 0.09; 95% CI, 0.01–0.81; P = 0.031) compared to the induction chemotherapy group. Conclusions: In hematologic malignancy-associated febrile neutropenia patients who remain hemodynamically stable and without documented infectious foci, the early de-escalation from carbapenem may be associated with better clinical outcomes. Prospective and multicenter studies are needed to confirm these findings.